What Is the Talc or Talcum Powder Ovarian Cancer Lawsuit?

Official sources: U.S. Judicial Panel on Multidistrict Litigation (JPML) | U.S. District Court for the District of New Jersey | U.S. Food and Drug Administration (FDA) | National Cancer Institute (NCI) | International Agency for Research on Cancer (IARC)

Litigation status reviewed: August 2026

What is the talc ovarian cancer lawsuit?

The litigation involves claims alleging that women developed ovarian cancer or certain other gynecological cancers after using talc-containing body powders, often over many years.

Plaintiffs generally allege that manufacturers knew or should have known about potential cancer risks associated with talc products and failed to provide adequate warnings.

Depending on the individual case and applicable law, claims may involve:

• Failure to warn
• Product liability
• Negligence
• Defective design
• Breach of warranty
• Other state-law theories

Johnson & Johnson has consistently denied that its cosmetic talc products cause cancer and disputes plaintiffs' allegations.

A diagnosis of ovarian cancer and a history of talc use do not, by themselves, establish that talc caused the disease.

What is talc?

Talc is a naturally occurring mineral made primarily of magnesium, silicon, and oxygen.

Because it absorbs moisture and reduces friction, talc has historically been used in products such as:

• Baby powder
• Body powder
• Facial cosmetics
• Personal care products
• Other cosmetic and consumer products

Talc deposits can occur geologically near asbestos, which creates a separate concern about possible contamination during mining or processing.

The FDA notes that asbestos is a known carcinogen and has conducted repeated testing of talc-containing cosmetics for asbestos contamination.

What products are involved in talc litigation?

The best-known lawsuits involve talc-containing products historically sold by Johnson & Johnson, including:

• JOHNSON'S® Baby Powder
• Shower to Shower® body powder

Other manufacturers and suppliers have also been involved in talc litigation.

The products, defendants, exposure histories, and alleged injuries vary among individual cases.

Johnson & Johnson discontinued sales of talc-based baby powder in the United States and later transitioned its global baby-powder portfolio to cornstarch-based formulations. The current litigation principally concerns historical talc use.

What cancer is alleged in the talc lawsuits?

The largest group of claims involves ovarian cancer.

Depending on the case, plaintiffs may allege:

• Epithelial ovarian cancer
• Fallopian tube cancer
• Primary peritoneal cancer
• Other gynecological cancers

Separate talc litigation has also involved mesothelioma, often based on allegations that talc products contained asbestos. See asbestos and mesothelioma lawsuits for how those claims work.

Those are related but scientifically and legally distinct categories of cases.

A talc/ovarian cancer claim should therefore not be treated as interchangeable with an asbestos-contamination mesothelioma claim.

Is there a talc MDL?

Yes.

Federal cases are centralized in:

In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation

MDL No. 2738

U.S. District Court for the District of New Jersey

The proceeding is currently assigned to U.S. District Judge Michael A. Shipp.

As of August 3, 2026, the JPML reported:

• 68,914 pending actions
• 71,601 total actions historically

in MDL 2738.

That makes it the largest active product-liability MDL in the federal court system by pending-case count at the time of this review.

Is the talc lawsuit a class action?

No.

MDL 2738 is multidistrict litigation, not a class action.

In an MDL:

• Individual lawsuits remain separate.
• Similar federal cases are coordinated before one judge.
• Common discovery and expert issues can be handled together.
• Individual claims can later settle, go to trial, be dismissed, or otherwise resolve.

Each plaintiff may have a different:

• Product-use history
• Cancer diagnosis
• Duration and frequency of talc use
• Medical history
• Exposure evidence
• Applicable state law
• Damages claim

Being part of an MDL does not mean everyone receives the same outcome or settlement.

What does the science say about talc and ovarian cancer?

The scientific evidence is complex, and different studies have reached different conclusions.

That distinction is essential.

Some case-control studies have reported an association between genital talc use and ovarian cancer.

Other prospective cohort studies have not found a statistically significant overall association.

The National Cancer Institute's current ovarian cancer prevention review summarizes this mixed evidence. It notes that some meta-analyses and case-control studies have found elevated ovarian-cancer risk associated with genital talc use, while prospective data have produced less consistent results.

That means the scientific literature does not support the simplistic statement that every use of talcum powder causes ovarian cancer.

What did IARC conclude about talc?

In 2024, the International Agency for Research on Cancer (IARC) reevaluated talc and classified it as probably carcinogenic to humans (Group 2A).

IARC's Working Group cited:

• Limited evidence for cancer in humans
• Sufficient evidence of cancer in experimental animals
• Strong mechanistic evidence

For ovarian cancer specifically, IARC found a positive association in several studies involving genital use of body powder containing talc, while also noting that bias in self-reported exposure could not be entirely ruled out.

IARC's classification is a hazard assessment. It identifies whether an agent is capable of causing cancer under some circumstances; it does not determine the cancer risk from every individual use or prove causation in a particular lawsuit.

What has the FDA said about talc?

FDA's position also requires nuance.

The agency has continued investigating both:

• The potential presence of asbestos in talc-containing cosmetics.
• Scientific evidence concerning talc itself and ovarian cancer.

An independent expert panel convened by FDA in 2025 reviewed scientific evidence concerning talc safety. FDA summarized the discussion as including decades of epidemiological research that has reported associations between cosmetic talc exposure and ovarian cancer.

FDA also continues to emphasize the separate issue of asbestos contamination, because asbestos is a known human carcinogen.

These are related but different scientific questions.

Talc vs. asbestos: what's the difference?

Talc and asbestos are different minerals.

Talc

A mineral widely used in cosmetic and personal-care products.

Asbestos

A group of fibrous minerals known to cause cancers including mesothelioma and lung cancer.

The concern arises because talc deposits can occur near asbestos deposits in the earth.

Poorly controlled mining or processing could therefore potentially allow asbestos fibers to contaminate talc.

FDA testing has at times detected asbestos in some sampled talc-containing cosmetic products, although the agency cautions that individual sampling surveys should not be interpreted as showing the overall prevalence of asbestos across the entire marketplace.

Does asbestos explain all talc ovarian cancer claims?

No.

There are two overlapping theories in talc litigation:

Talc itself

Some studies and lawsuits examine whether repeated genital or perineal use of talc may be associated with ovarian cancer even apart from asbestos contamination.

Asbestos-contaminated talc

Other claims allege that talc products contained asbestos and that asbestos exposure caused disease.

These theories involve different scientific evidence.

It would therefore be inaccurate to say that every ovarian cancer claim depends on proving asbestos contamination.

Who may be affected by the talc ovarian cancer litigation?

Potential claims have generally involved women who:

• Used talc-based body powder in the genital or perineal area.
• Used the products repeatedly or for an extended period.
• Were later diagnosed with ovarian or another qualifying gynecological cancer.
• Can provide evidence concerning product use and medical diagnosis.
• Meet applicable filing deadlines and current litigation requirements.

Relevant factors can include:

• Product used
• Years of use
• Frequency of use
• How the product was applied
• Age when use began
• Cancer type
• Diagnosis date
• Family and medical history
• Other ovarian cancer risk factors

Product use alone does not establish a claim.

What evidence may matter in a talc case?

Potential evidence can include:

Product-use evidence

• Purchase records
• Photographs
• Product containers
• Family statements
• Household-use history
• Retail records
• Brand recollection
• Frequency and duration of use

Medical evidence

• Pathology reports
• Oncology records
• Cancer diagnosis
• Surgical records
• Treatment history
• Genetic testing
• Family cancer history
• Other relevant medical records

Because alleged exposure may have occurred over decades, plaintiffs may not have every old receipt or product container.

Other evidence may help reconstruct product use.

Do you need old receipts?

Not necessarily.

Many plaintiffs allege use beginning decades before their cancer diagnosis.

It is therefore common for old purchase receipts to no longer exist.

Potential supporting evidence may include:

• Family-member testimony
• Photographs
• Consistent product histories
• Product containers
• Retail or loyalty records
• Statements from people who observed the use

The sufficiency of evidence depends on the individual case and applicable law.

What happened with Johnson & Johnson's bankruptcy attempts?

Johnson & Johnson pursued multiple efforts to resolve large portions of its talc liabilities through bankruptcy proceedings involving subsidiaries created to hold talc-related liabilities.

Those efforts were repeatedly challenged.

The most recent proceeding involved Red River Talc LLC, which sought approval of a Chapter 11 plan designed to resolve ovarian and other gynecological cancer claims.

On March 31, 2025, the U.S. Bankruptcy Court for the Southern District of Texas denied confirmation and dismissed the bankruptcy case.

Johnson & Johnson subsequently announced that it would not appeal and would return to the civil tort system to litigate the claims.

That history matters because many older online articles still describe a proposed bankruptcy settlement as though it became final.

It did not.

Is there now a new talc settlement proposal?

Yes.

On July 27, 2026, Johnson & Johnson announced a proposed resolution of the remaining ovarian-talc litigation.

The company said the proposal:

• Requires participation from plaintiff firms representing at least 95% of remaining ovarian talc claims.
• Calls for a $5.5 billion commitment by Johnson & Johnson.
• Provides for per-claim payments.
• Contemplates an initial payment of no more than $3 billion in 2027, with no additional payments due before 2028.

The proposal is intended to resolve ovarian talc claims in both state and federal courts.

This is a major development—but it is important to describe it accurately.

It is a proposed resolution subject to participation and other conditions, not proof that every talc plaintiff has already settled.

Has the talc lawsuit settled?

Not completely.

As of the August 2026 review:

• Johnson & Johnson has announced a proposed $5.5 billion ovarian-talc resolution.
• The agreement is conditioned on substantial claimant participation and other criteria.
• MDL 2738 still appears on the JPML's August 3, 2026 active-MDL report with 68,914 pending actions.

Johnson & Johnson has separately reported resolving much of its mesothelioma litigation and other talc-related disputes, but those settlements should not be confused with the ovarian-cancer claims addressed by the new proposal.

How much will talc plaintiffs receive?

There is no single universal payout amount that applies to every plaintiff.

Johnson & Johnson's July 2026 proposal calls for per-claim payments, but individual compensation can depend on the terms of the eventual agreement and the circumstances of each claim.

Factors may include:

• Cancer diagnosis
• Medical history
• Product-use history
• Duration and frequency of use
• Age
• Disease severity
• Treatment
• Damages
• Applicable settlement criteria
• Participation in any approved resolution process

A headline settlement amount divided by the number of cases is not a reliable estimate of what an individual claimant would receive.

Are ovarian cancer and mesothelioma claims treated the same way?

No.

This is another important distinction.

Ovarian and gynecological cancer claims

These are the primary claims addressed by the July 2026 proposed ovarian-talc settlement.

Mesothelioma claims

These generally involve allegations of asbestos exposure through contaminated talc.

Johnson & Johnson has said it has separately resolved most filed mesothelioma lawsuits.

Different disease categories can therefore have different evidence requirements, legal theories, defendants, and settlement structures.

Is talc still used in cosmetics?

Yes.

Talc remains an ingredient in some cosmetic and consumer products.

FDA continues to oversee cosmetic safety and has conducted testing related to asbestos contamination in talc-containing products. Its talc information page was updated in January 2026 and includes testing results and regulatory information.

Consumers should not assume that every product containing talc is part of the Johnson & Johnson litigation.

Is there a deadline to file a talc lawsuit?

Yes.

Product liability and personal injury claims are subject to statutes of limitation.

The applicable deadline can depend on:

• State law
• Date of diagnosis
• Date the alleged connection to talc reasonably could have been discovered
• Product-use history
• Type of claim
• Other individual circumstances

Settlement programs may also impose separate participation or registration deadlines.

The existence of a massive MDL does not eliminate filing deadlines.

Common misconceptions

Myth: Johnson & Johnson's new $5.5 billion agreement means every talc lawsuit is settled and every plaintiff will receive the same payment.

Reality: The July 2026 proposal is a conditional resolution of remaining ovarian-talc claims that requires participation from firms representing at least 95% of the remaining claims. MDL 2738 remained active as of August 3, 2026, and any individual payment depends on the final settlement structure and the claimant's circumstances.

Why this matters

Talc litigation is difficult to understand because several different stories are happening at once:

• Ovarian cancer claims.
• Mesothelioma and alleged asbestos-contamination claims.
• Conflicting or nuanced epidemiological evidence.
• IARC's classification of talc as probably carcinogenic.
• FDA's continuing examination of talc safety and asbestos testing.
• Three unsuccessful bankruptcy efforts.
• A new multibillion-dollar proposed ovarian-cancer resolution announced in July 2026.

A trustworthy explanation has to keep those issues separate.

The existence of a large lawsuit does not itself prove causation.

At the same time, it is also inaccurate to say there is no scientific concern: IARC now classifies talc as probably carcinogenic to humans, and multiple epidemiological studies have reported associations between genital talc exposure and ovarian cancer.

Take the next step

• Understand mass torts
• Learn about Product Liability
• Explore multidistrict litigation (MDL)
• Learn about Ovarian Cancer
• Understand asbestos and mesothelioma lawsuits
• Screen for current mass tort programs